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The analysis of the outcome and the risk factors of failure 
in early breast cancer patients after breast conserving therapy
Anna Niwiƒska1, Jacek Ga∏ecki2, Monika Nagadowska1, Wojciech Michalski3
A i m.  To assess the outcome and to analyze the risk factors of failure and death in breast cancer patients treated with
breast conserving therapy.
M a t e r i a l  a n d  m e t h o d.  184 breast cancer patients in stage I and II were treated conservatively at the Maria Sklodowska-
Curie Memorial Cancer Center and Institute of Oncology in Warsaw, between 1995 and 1998. The time of observation was 48-
84 months, median time – 70 months. In 53% of patients (98/184) adjuvant chemo- and/or hormonotherapy was introduced.
The probability of local recurrence, disease free survival and overall survival were assessed using the Kaplan-Meier method.
Risk factors of local/distant failures analyzed were analyzed with Cox’s regression model and covered the following: age,
hormonal status, familial breast cancer, laterality of the breast, medial versus other breast tumor location, non-palpable disease
(lesions only in mammography) vs palpable, pathological stage pT and pN, number of excised or involved axillary nodes,
histological type and grade of cancer, presence or lack of intraductal component and size of healthy tissue margin around the
tumor.
Re s u l t s.  Recurrence (local recurrence or /and distant metastases) occurred in 9.8% of patients (18/184). Local recurrence
was found in 5.5% of patients (10/184). The probability of 5-year disease free survival and 5-year overall survival was 91% and
97%. Based on multivariate analysis the only statistically significant risk factor of recurrence or death was palpable disease
(p<0.01). The risk of failure was 6.7 fold higher in patients with palpable tumours, as compared to those with non palpable
disease in the breast. The diameter of the tumor was, statistically, the most important risk factor of death (p<0.01). Patients
with pT2 tumours had an 8.4 fold higher risk of death as compared to pT1 patients.
C o n c l u s i o n s.  The results of breast conserving therapy performed in stages I and II of breast cancer (at the Maria
Sklodowska-Curie Memorial Cancer Center and Institute of Oncology) are comparable to the published ones and demonstrate,
that patients were adequately qualified and treated. The most important risk factor of failure and death was the size of the
tumor. The best prognosis characterizes patients with pre-clinical breast cancer, where the primary tumor may be detected only
mammographically and is less than 2 cm in diameter.
Analiza wyników i czynników ryzyka nawrotu u chorych na raka piersi po leczeniu oszcz´dzajàcym 
we wczesnym stopniu zaawansowania
C e l.  Ocena wyników leczenia i analiza czynników ryzyka nawrotu i zgonu u chorych na raka piersi po leczeniu
oszcz´dzajàcym.
M a t e r i a ∏  i m e t o d a.  W Centrum Onkologii w Warszawie w latach 1995-1998 leczono w sposób oszcz´dzajàcy 184 kobie-
ty chore na raka piersi w I i II stopniu zaawansowania. Czas obserwacji wynosi∏ 48-84 miesiàce, mediana – 70 miesi´cy.
U 53% chorych (98/184) zastosowano uzupe∏niajàcà chemio- lub/i hormonoterapi´. Prawdopodobieƒstwo prze˝ycia oblicza-
no metodà Kaplana-Meiera. Wp∏yw potencjalnych czynników prognostycznych na czas prze˝ycia ca∏kowitego i czas prze˝ycia
bezobjawowego analizowano pos∏ugujàc si´ modelem proporcjonalnego ryzyka Cox’a. Do analizy w∏àczono nast´pujàce czyn-
niki: wiek, stan hormonalny, rodzinne wyst´powanie raka piersi, strona piersi, lokalizacja raka w gruczole piersiowym przyÊrod-
kowa versus inna, postaç przedkliniczna (rak stwierdzany tylko w mammografii) vs postaç kliniczna, stopieƒ zaawansowania
pT, pN, liczba usuni´tych lub zaj´tych w´z∏ów ch∏onnych, typ i stopieƒ z∏oÊliwoÊci histopatologicznej raka, obecnoÊç kompo-
nentu CDIS (raka przedinwazyjnego) w raku inwazyjnym i szerokoÊç marginesów tkanek zdrowych wokó∏ raka.
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Introduction
Breast conserving therapy provides an alternative to
mastectomy in patients with early breast cancer. If the
choice of patients is appropriate the late results of
treatment are as good as in the case of mastectomy, while
its supremacy lies in organ preservation [1, 2]. This is
very important in view of the modern approach to cancer
treatment, where quality of life is becoming an issue of
increasing importance.
The first institution in Poland to introduce breast
conserving therapy and to publish early results was the
Clinic of Oncological Surgery of the Medical Academy in
¸ódê, where first such procedures were performed in
1981 [3, 4]. Over the next years many other oncological
institutions adapted this method. Until today numerous
papers concerning this issue have been published in
Poland, devoted not only to the efficacy of breast
conserving therapy, but also to the quality of life and to
the aesthetic effect of this modality [3-11]. At the Maria
Sklodowska-Curie Memorial Cancer Center and Institute
of Oncology in Warsaw the protocol for breast conserving
therapy had been prepared and introduced in 1984. One
of its authors is now the co-author of this publication
(MN). The method was widely introduced in 1995, after
the establishment of the Department of Breast Cancer
and since then it has been one of the main research fields
at our institution [12]. Our previous papers have
presented our experiences regarding treatment tolerance,
complications and the psychological aspects of breast
conserving therapy [6-8, 10, 11]. Basing upon the
evaluation of 100 patients treated at our department
between the years 1995 and 1997 after a follow-up period
of 29 months the aesthetic effect was evaluatedh as
excellent and very good in 88% of cases. However,
concomitant chemotherapy and radiotherapy decreased
the likelihood of achieving an excellent aesthetic effect.
Similarly, a boost to the tumour site achieved through
the implantation of Ir 192 provided a worse aesthetic
effect than electron treatment; however this data must
be carefully approached, as it originated from the time of
our early experiences with breast brachytherapy [8]. We
had concluded that treatment tolerance is good, but
adjuvant radio-chemotherapy increases the duration of
systemic treatment [6]. A majority of patients (87%) were
satisfied with breast conserving treatment [10]. After
three years of follow-up the main complication we had
observed was oedema of the upper extremity induced by
axillary lymphadenectomy. It was recognized in 10% of
patients, however in a majority of them (88%) the
difference in diameter between the two upper extremities
did not exceed 2-4 cm [11].
The aim of the present paper is to summarise and
evaluate the results of breast conserving therapy,
including the ratio of local failures, time to recurrence
and overall survival and to analyze the risk factors of
treatment failure.
Material and method
Breast conserving therapy (BCT) is being performed at the
Maria Sklodowska-Curie Memorial Cancer Center and Institute
of Onocology in Warsaw since 1995. Between January 1995 and
December 1998 BCT was performed in 197 patients with breast
cancer in stage 0, I and II. 184 patients stage I and II were fianlly
included in this analysis, the remaining 13 patients had
preinvasive breast cancer and will form the subject of a diffe-
rent analysis. Follow-up time was 48 to 84 months; median: 70
months.
Patient characteristics are presented in Table I. Mean age
was 52 yrs; approx. 2/3 of the patients were pre-menopausal.
Pre-clinical stage tumours (recognized in mammography only)
were found in 72/184 pts (34%). The first stage of BCT consisted
of lumpectomy (169/184 – 92%) or quadrantectomy (15/184 –
8%) and axillary lymphadenectomy of all three levels of lymph
nodes. The median number of excised lymph nodes was 16. All
patients were operated radically, with negative margins. If the
lumpectomy margins were found to contain cancerous cells
or the margin was less than 1 mm the patients were re-operated
to achieve normal tissue margins (29 cases). Only in 5%
of patients initially treated outside the MSCMCC the size of
the margins was not evaluated pathologically in milimeters,
although the samples were consulted and the procedure was
pronounced as radical. All these patients had undergone
quadrantectomy.
Tumours below 2 cm in diameter were found in 154/184
(83%) of patients; 2-3 cm in 17% of patients. In 141/184 (77%)
of pts. the axillary lymph nodes we not affected (pN0), while in
the remaining 43/184 (23%) of patients the axillary lymph nodes
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W y n i k i.  Nawrót choroby (wznowa miejscowa lub/i przerzuty odleg∏e) stwierdzono u 9,8% chorych (18/184). Wznowa
miejscowa wystàpi∏a u 5,5% chorych (10/184). Prawdopodobieƒstwo 5-letniego prze˝ycia bezobjawowego i ca∏kowitego
wynosi∏o odpowiednio 91% i 97%. Na podstawie analizy wieloczynnikowej jedynym istotnym statystycznie czynnikiem,
majàcym zwiàzek z ryzykiem wystàpienia nawrotu lub zgonu, by∏a postaç kliniczna raka (p<0,01). Chore z klinicznie
stwierdzanym rakiem mia∏y 6,7 razy wy˝sze ryzyko nawrotu ni˝ chore z rozpoznaniem przedklinicznej postaci raka. Na
ryzyko zgonu istotny statystycznie wp∏yw mia∏a wielkoÊç guza (p<0,01). Chore z rozpoznaniem pT2 mia∏y 8,4 razy wy˝sze ryzyko
zgonu ni˝ chore z pT1.
W n i o s k i.  Wyniki oszcz´dzajàcego leczenia chorych na raka piersi w stopniu I i II, przeprowadzonego w Centrum Onkologii
w Warszawie, sà porównywalne z danymi z piÊmiennictwa i Êwiadczà o w∏aÊciwym doborze chorych oraz o poprawnie
przeprowadzonym leczeniu. Najwa˝niejszym czynnikiem ryzyka nawrotu choroby lub zgonu po leczeniu oszcz´dzajàcym
jest wielkoÊç guza pierwotnego. Najlepsze rokowanie majà chore z przedklinicznà postacià raka (rak wykryty na podstawie
mammografii) z guzem o Êrednicy do 2 cm.
Key words: breast cancer, conservative treatment
S∏owa kluczowe: rak piersi, leczenie oszcz´dzajàce
contained metastases. After surgery the patients underwent
irradaiation with a cobalt beam to the breast (102 pts) or with X
photons 4MeV (82 pts) from 2 diagonal fields with the isocenter
technique in 2 Gy conventional fractions to the total dose of 50
Gy over 5 weeks. Then we applied a boost to the tumour site
(increased by 10 Gy) with an electron beam of individually
assigned energy (113 pts) or with HDR brachytherapy (Ir 192)
(71 pts). 3D treatment planning was performed with the aid of
a simulator and CT scanning. The irradiated volume consisted of
the breast, with CT planes every 2 cm. The irradiated areas
were drawn into each plane. The method was consistent with
ICRU 50 regulations (as described in an earlier paper) [13].
During treatment planning extra care was taken to shield the
organs at risk (i.e. the heart and the lungs). Radiotherapy as
the sole adjuvant modality or in conjunction with tamoxifen
hormonotherpy was initiated 4-8 weeks after surgery. Post-
operative chemo- and/or hormonotherapy was administered to
99 pts (54%). CMF chemotherapy (cyclophosphamide, metho-
trexate and 5-FU) was administered to 50 pts; epirubicine/CMF
chemotherapy to 2 pts and AC chemotherapy (adriamycine,
cyclophosphamide) to 2 pts. Tamoxifen hormonotherapy was
administered to 60 pts, of which 15 received it after previous
chemotherapy. Patients treated acc. to the CMF program were
administered radiotherapy to the affected breast simultaneously
with chemotherapy. Irradiation was initiated after the second
course of CMF. Patients administered anthracyclines were
treated sequentially, i.e. irradiation was applied after chemo-
therapy. In the case of 9 pts (5%) in whom metastases were
present in more than 3 axilllary nodes radiation therapy was
applied to the breast and to the regional lymph nodes. In these
patients radiotherapy was also applied after the completion of
chemotherapy.
We analyzed overall survival (OS) and disease free survival
(DFS). The first confirmed recurrence of the malignancy was
considered as failure (local failure and/or distant metastases or
death). Survival probability was calculated acc. to the Kaplan-
Meier method. The influence of potential prognostic factors on
OS and DFS was analyzed acc. to Cox’s proportional hazards
model, which included the following prognostic factors: age,
hormonal status of pts, familial breast cancer occurrence, the
side of the disease, localization within the breast (paramedial vs.
others), pre-clinical disease (recognized in mammography only)
vs clinical stage, pT stage, pN, the number of excised and
metastatic lymph nodes, type and grade of histopathological
malignancy, presence of DCIS (a component of pre-invasive
cancer) within invasive tumours and the healthy tissue margins
around the tumour.
In the modeling process we applied a technique of stepwise
elimination including (in course) the variable for which the
critical test value (p) was the greatest, but not less than p = 0.1.
Statistical significance level was set at 0.05.
Results
Recurrence was observed in 18/184 pts (9.8%) – in 10
cases local (5.5%) and in 8 – distant metastases (4.3%).
Of the 10 pts with local failure in 7 the recurrence
occurred in the tumour site, in 2 – outside the tumour
site and in 1 case recurrence within the tumour site was
accompanied by metastases to regional lymph nodes. The
time to local recurrence varied between 14 to 72 months
from the termination of primary treatment. Table II
presents the characteristics of the 10 pts. with local failure,
including the risk factors.
The time to distant metastases varied between 10
and 72 months. Death due to metastases occurred after
27-66 months.
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Table I. Clinical characteristics of 184 patients
No. of patients 184 (100%)
Age (yrs) min 25. max 76, mean: 52
25-45 yrs 62 (33)
46-55 yrs 63 (34)
56-75 yrs 62 (33)
Menopausal status
Pre-menopausal 127 (69)
Post-menopausal 57 (31)
Familial breast cancer:
No 164 (89)
Yes 20 (11)
Breast:
Right 80 (43)
Left 104 (57)
Tumour localisation within the breast:
Medial 63 (34)
Other 121 (66)
Cancer stage:
Pre-clinical 72 (39)
Clinical 112 (61)
Advancement grade:
I 150 (82)
II a 28 (15)
II b 6 (3)
pT1a + pT1b 65 (36)
pT1c 89 (48)
pT2 30 (16)
pN0 141 (77)
pN1 43 (23)
No. of excised nodes: Min. 5, max. 34, mediana 16
No. of involved nodes:
0 141 (77)
1-3 34 (18)
>3 9 (5)
Histopathological type of tumour:
Carcinoma ductale 115 (63)
Carcinoma lobulare 36 (19)
Other types 33 (18)
Grade of histological malignancy
G1 41 (22)
G2 53 (29)
G3 42 (23)
No evaluation 48 (26)
CDIS component in invasive cancer:
Yes 50 (27)
No 134 (73)
Margins around tumour:
1-2 mm 36 (19)
3-5 mm 47 (26)
>5 mm 91 (50)
No data 10 (5)
Treatment methods:
BCS + RT 85 (46)
BCS + RT + CT 39 (21)
BCS + RT + HTH 45 (25)
BCS + RT + CT + HTH 15 (8)
BCS – Breast Conserving Therapy, RT – Radiotherapy, CT –
Chemoterapy, HTH – hormonotherapy
In 10/184 pts. (5.4%) we discerned a second
malignancy: in 6/184 (3.2%) cancer of the ipsilateral
breast, in the remaining cases ovarian cancer, endometrial
cancer, lung cancer and meningioma.
5-year OS and DFS with a 95% confidence interval
was 97% (95%, 99%) and 91% (88%, 94%), respectively
(Figures 1 and 2). 5-year survival without local recurrence
was 95%.
The results of the regression analysis are presented
in Tables III and IV. In a multivariate analysis the only
statistically significant factor (p<0.01) influencing the
risk of recurrence (local failure and/or distant metastases)
or death was the clinical stage of the malignancy. Patients
with clinically discernible cancers had a 6.7 times higher
risk of recurrence or death than patients with pre-clinical
tumours (discernible in mammography only). The risk of
death was statistically significantly associated with the
size of the breast tumour (pT) (p<0.01). In case of pT2
tumours the risk of death was 8.4 times higher than in
the case of lesser tumours. We also discerned the
significant influence of the number of excised lymph
nodes on the risk of death (p<0.04). The relative risk
was 1.12, i.e. a mean increase in the risk of death by 12%
for each excised lymph node. DFS and OS survival for the
most imminent prognostic factors listed above evaluated
acc. to Cox’s multivariate analysis is presented on
Figures 3 and 4. Basing upon Cox’s model of proportional
hazards we have not discerned the influence of age,
hormonal status, familial occurrence of breast cancer the
side of the disease, localization within the breast
(paramedial vs. others), pN, the type and grade of
histopathological malignancy and presence of DCIS (a
component of pre-invasive cancer) within invasive
tumours on either OS and DFS.
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Table II. Characteristics of 10 patients with local or locoregional
recurrence
Factor Ratio of patients with recurrence
Advancement:
Grade I 6/150 – 4%
Grade II 4/34 – 11%
Stage:
Pre-clinical 1/72 – 1.3%
Clinical 9/112 – 8%
Age:
≤ 40 yrs of age 3/18 – 17%
> 40 yrs of age 7/179 – 4%
Healthy tissue margins:
1-2 mm 2/36 – 5%
>2 mm 8/148 – 5%
CDIS component:
Yes 7/50 – 14%
No 3/134 – 2%
Histological malignancy G:
1 and 2 3/94 – 3%
3 7/42 – 16%
Nodal metastases:
Yes 1/43 – 2%
No 9/141 – 6%
Adjuvant therapy (chemo-; hormono-)
Yes 7/99 – 7%
No 3/85 – 4%
Figure 1. Overall survival of 184 patients with early breast cancer after
breast conserving therapy
Figure 2. Disease-free survival of 184 early breast cancer patients after
breast conserving therapy
Table III. Results of Cox’s regression model analysis – risk of failure 
(local recurrence or/and distant metastases)
Variable Beta factor Standard Critical test Relative 
deviation level (p) risk (RR)
Clinical form 1.894 0.747 0.01 6.7
Table IV. Results of Cox’s regression model
Variable Beta factor Standard Critical test Relative 
deviation level (p) risk (RR)
pT2 vs pT1 2.128 0.821 0.01 8.4
No. of excised nodes 0.113 0.056 0.04 1.12
Discussion
According to published data the risk of local failure in
pts. with breast cancer after BCT (chemo- and radio-
therapy) after 10 yrs of follow-up reaches 10-15% [2, 14-
19]. Irradiation after BCT in advancement stage I and II
reduces the risk of local failure by 30-40%, especially in
patients with T2 tumours, infiltration of lymphatic vessels
and axillary lymph node involvement [14]. Radiotherapy
provides 6-9% of benefits for long-term OS, however in
T1 pts with no nodal involvement the OS benefit is lower,
not exceeding 5% [14].
Basing upon the results of prospective, randomized
clinical trials it has been found that the risk of local failure
after BCT and mastectomy is comparable [2, 15-19] and
varies between 5% and 16%. In numerous retrospective
studies the risk of local failure is 4-16% after 5-8 yrs; 10-
21% after 10-12 yrs and 12-23% after 15 yrs [20-29].
In our material the ratio of local failures after 5 years
of follow-up was 5.5%. This is similar to other published
results and proves the adequate choice of patients at the
onset of treatment and the correct course of surgery and
adjuvant treatment.
In our patient material 5-year OS and DFS after
BCT was 97% and 91%, respectively. This data is also
consistent with that from literature, both Polish and
international. Acc. to the results published by Jeziorski
and Berner [3] 5-year OS and DFS was 97.8% and 93.4%
respectively. Acc. to Jodkiewicz et al. [5] 5-year OS and
DFS after BCT was 97% and 93%, respectively. In the
study of Touboul et al. [25] performed on 528 women
with breast cancer below 3 cm in diameter 5-year and 10-
year OS after BCT was 93% and 86%, respectively, while
DFS was 85% and 75%, respectively. In the study of
Fredriksson [30], who had performed an analysis of 6613
pts who had undergone BCT the 5-year and the 10-year
cancer associated survival was 84.5% and 70.9%,
respectively. In other, less recent studies, 5-year survival
after BCT varied between 50% and 84% [22, 31, 32].
R i s k  f a c t o r s  o f  l o c a l  f a i l u r e  a n d  d i s t a n t
m e t a s t a s e s
Literature reports list a number of risk factors affecting
local failure and distant metastases after BCT. Some are
more characteristic for local failure, while others more
typical for dissemination. There also exist some predictive
factors for both these clinical situations.
Among factors listed as affecting local failure after
BCT one finds young age, large tumour mass, multifocal
carcinoma, high degree of histological malignancy, high
component of DCIS and the size of the healthy tissue
margin around the tumour. The most common risk
factors of dissemination after BCT include age below 35
yrs, the size of the primary tumour, axillary lymph node
involvement, high grade of histopathological malignancy,
invasion of cancer cells into vessels, lack of estrogen and
progesterone receptors within the cancer cells and local
failure [14, 25, 26, 28].
In our study we have not analyzed vessel infiltration
and the presence of estrogen receptors, because they
were only evaluated in approx. half of the patients.
Pa t i e n t  a g e
The most important risk factor of local failure, confirmed
in numerous retrospective studies and in large rando-
mized trials is patient age. In women below 35 yrs. of age
the risk of local failure after BCT reaches some 24%-
43% after 8-10 yrs. of follow-up [20-25, 33-37]. It remains
high in the 35-40 yr. age group [26, 29, 38, 39]. Voogd et
al. [34] have shown an over 9-fold increase in the risk of
local recurrence in women below 35 yrs of age, as
compared to women over 60 yrs of age. Arriagada [37]
reports a higher local failure ratio in women before 40 yrs.
of age. In a randomized EORTC clinical trial performed
by Bartelink et al. [40] it has also been shown that the
recurrence risk was significantly dependant on patient
age. Patients below 40 yrs. of age had the greatest risk
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Figure 3. Disease-free survival of 184 early breast cancer patients
after breast conserving therapy- preclinical versus clinical disease
Figure 4. Overall survival in 184 early breast cancer patients
after breast conserving therapy – pT1 versus pT2
of recurrence and were the ones to benefit the most from
a boost to the tumour site (19.5% of recurrences in the
first 5 yrs in the “no-boost” group, as compared to 10.2%
after a 16 Gy boost). Young age is considered a risk factor
of not only local recurrence, but also of developing distant
metastases [41].
We divided our patient material into 3 age groups
and evaluated the recurrence risk separately in each of
these groups. We failed to show that age was a risk factor
of recurrence or death. One of the reasons for such
a result could be the relatively low ratio of treatment
failures. At the same time in Table III we have shown
that patients below 40 yrs. of age are at a greater risk of
developing local recurrence, as compared to older
women, which is similar to other literature reports.
H i s t o p a t h o l o g i c a l  c h a r a c t e r i s t i c s  o f  t h e
t u m o u r
The local failure risk is higher in the case of multifocal
tumours and reaches some 36-40% [25, 35, 36, 38, 42]. In
the study of Touboul [25] it has been shown that
microscopically bi-focal tumours up to 1 cm in diameter at
a distance of less than 1 cm from one another pose as
a risk factor of local failure despite healthy tissue margins
of at least 2 mm. Vessel involvement around the primary
tumour increases the risk of recurrence and dissemination
[25, 35, 36, 42, 43].
A number of studies have shown that the presence of
invasive or pre-invasive cancer cells within the healthy
tissue margins surrounding the tumour increases the risk
of local recurrence 2-3 times during a 10-year follow-up
period [23, 29, 36, 42, 44-46]. After 5 years of follow-up
local recurrence in patients in whom cancer cells were
found in the healthy tissue margin reached 2-22.5%, while
with free healthy tissue margins – 2-7% [18, 47]. In the
course of the study of Park et al. [44] performed on 533
patients it has been shown that after 8 years of follow-up
the local failure risk in patients with large and close
margins was 7%, while in patients with the presence of
cancer cells within the margins – 27%. Such correlations
cannot be found in the course of studies where margins
were routinely increased or where the boost to the
tumour site was increased to 20-25 Gy [25].
The presence of extensive EIC components increases
the risk of local failure [25, 34-36, 39, 48-50]. The reason
behind this is probably the fact that in cases of large
residue component of CDIS within the tumour margins it
may be difficult to discern residual disease, even in places
relatively distant from the primary tumour [48]. EIC is
a typical risk factor of local recurrence, but not of distant
metastases [14, 25, 34].
Among the different histological types of breast
cancer only lobular carcinoma, especially multifocal, poses
the greatest risk of local failure [39, 51, 52]. The high
grade of histological malignancy may increase the risk of
local failure, however not all authors support this theory
[25].
At our institution we have introduced a system of
qualification of patients for BCT as early as in 1995.
Patients with multifocal tumours were not qualified for
BCT, therefore we cannot perform an analysis of this
particular risk factor. All patients were radically operated,
achieving negative margins. We have performed
a statistical analysis of the size of the healthy tissue margin
(1-2 mm; up to 5 mm and over 5 mm) on the risk of
recurrence, but arrived at no conclusive results. In our
study group we did not observe an increased risk of
recurrence related to the presence of the pre-invasive
cancer component. Neither did we observe any relations
between the risk of recurrence and the histopathological
type of tumour. It may arise from the fact that lobular
carcinoma, which poses the greatest risk of recurrence,
was significantly less common in our patient material.
Recurrence analysis has shown, that 9 out of 10 recurren-
ces were related to ductal carcinoma, and only one out of
ten to lobular carcinoma. To summarise, in the course of
our study we have failed to find any statistically significant
correlations between the histological type of tumour and
the risk of local, locoregional or distant failure. This
probably arises from the strictly followed protocol which
sets exact criteria for patient qualification and forces the
necessity of increasing healthy tissue margins.
T N M  s t a g e
Numerous authors have stressed the higher ratio of
failures in patients with tumours greater than 1.5 cm [24],
and especially in tumours greater than 2 cm, as compared
to patients with smaller cancers [17, 18, 26, 29, 42, 43,
49, 53]. Also, there exist reports concerning the corre-
lation between axillary lymph node involvement and the
ratio of distant metastases [24].
In our material we have found that the stage of
clinical advancement was the main cause of recurrence.
Only patients with tumours of less than 3 cm were
qualified for BCT, but the statistical analysis was
performed basing upon the histopathological results
concerning the pT characteristic. The risk of recurrence
for clinically evident tumours was 6.7 times greater than in
the case of pre-clinical tumours (i.e. discerned only in
mammography). We have also found that in case of pT2
tumours the risk of death was 8.4 times higher than in
the case of lesser tumours. Similar results have been
reported in literature. In our material we have not con-
firmed the influence of axillary lymph node involvemenmt
on prognosis. However, the number of patients with
axillary lymph node involvement is very low in our
material. On the other hand we did find that the risk of
death increases statistically significantly (p<0.04) with
the increase in the number of resected axillary nodes.
The interpretation of this result is complex and demands
further studies. In order to arrive at an explanation for
such a phenomenon we have investigated whether there
exists some form of relation between the number of
excised nodes and the stage of cancer advancement. We
assumed that in patients with more advanced disease the
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surgeon removes a greater number of lymph nodes.
Statistical analysis has shown that there exists no
correlation between the number of resected lymph nodes
and the TNM stage, the tumour size and the number of
nodal metastases found during the histopathological
examination (chi-square test: p=0.389, p=0.96 and
p=0.49, respectively).
A d j u v a n t  t h e r a p y
Systemic adjuvant treatment decreases the risk of local
failure and of distant metastases [24, 38, 41, 44, 54-56].
Tamoxifen hormonotherapy [55] not only reduces the risk
of recurrence, but also reduces the risk of cancer of the
ipsilateral breast. In the study published by Mirza [24]
patients on tamoxifen hormonotherapy had a 66% lower
risk of local recurrence, as compared to patients not
receiving hormonotherapy. Freedman et al. [57] have
shown that adjuvant tamoxifen treatment in patients over
55 years of age was the most important factor reducing
the risk of local recurrence. In patients between 36 and 55
years of age with ER and PR positive cancers the
recurrence risk was 5% in those taking tamoxifen, and
20% in pts who were not on tamoxifene. Elkhuizen et al.
[38] have concluded that chemotherapy reduces the local
recurrence risk by 50% in patients below 43 yrs of age.
Bucholtz et al [54] had observed 484 pts. with breast
cancer without axillary lymph node involvement and
found that systemically treated patients (chemotherapy,
chemotherapy and tamoxifen or tamoxifen) have a 10%
better local control after 8 years of follow-up. Thus it has
been confirmed that tamoxifen as a sole modality, and
chemotherapy also, provide benefits for local recurrence-
free survival. According to the research team from the
Dana Faber Hospital the delay in radiotherapy caused
by sequential treatment consisting of chemotherapy
followed by radiotherapy increases the risk of local failure
[59], but Froud et al. [59] have not shown any differences
in the ratio of local recurrence among low risk patients (in
an entire group of 1962 patients) who began radiotherapy
during a period of 20 weeks after surgery in the course of
BCT and did not receive cytostatics over this time period.
A majority of our patients who had received cytostatics
(45/54 – 83%) were undergoing concomitant chemo-
radiotherapy, which could have also had an impact on
the good treatment results.
The analysis of our patient material has shown that
in the case of breast cancer patients there exists a strong
correlation between the size of the tumour (pre-clinical vs
clinical and pT1 vs pT2) and the frequency of treatment
failures (Figures 3, 4). These results are fully supported by
data from literature. It appears that the relatively low
risk of local failures and distant metastases arises from the
correct choice of patients during initial qualification (early
stages of disease, no cases of multifocal carcinoma) and
adequately performed surgery (wide healthy tissue
margins around the excised tumour) and adjuvant
therapy.
Conclusions
1. The results of BCT in patients with breast cancer stage
I and II treated at the Maria Sklodowska-Curie
Memorial Cancer Cnter and Institute of Oncology in
Warsaw are similar to those reported by other
institutions and provide proof of appropriate patient
qualification and treatment performance.
2. The most important risk factor of recurrence or death
after BCT is the size of the primary tumour. Patients
with pre-clinical tumours (discerned in mammography
only) below 2 cm in diameter have the best prognosis.
Anna Niwiƒska MD, PhD
Department of Breast Cancer and Reconstructive Surgery
Maria Sk∏odowska-Curie Memorial Cancer Center
and Institute of Oncology
Roentgena 5, 02-781 Warsaw
Poland
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